REduced Frequency ImmuNE Checkpoint Inhibition in Cancers

NCT04913025 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Melanoma

Interventions

DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

University College, London

Collaborators

[object Object]